PUBLISHER: TechNavio | PRODUCT CODE: 2056115
PUBLISHER: TechNavio | PRODUCT CODE: 2056115
Global Neurodegenerative Diseases Therapeutics Market 2026-2030
The global neurodegenerative diseases therapeutics market is forecasted to grow by USD 26492.5 mn during 2025-2030, accelerating at a CAGR of 9.0% during the forecast period. The report on the global neurodegenerative diseases therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rapidly aging global demographic and rising disease prevalence, breakthroughs in biomarker discovery and early diagnostic technologies, increased funding and favorable regulatory pathways.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
| Market Scope | |
|---|---|
| Base Year | 2025 |
| End Year | 2030 |
| Series Year | 2026-2030 |
| Growth Momentum | Accelerate |
| YOY 2026 | 8.3% |
| CAGR | 9% |
| Incremental Value | $26492.5 mn |
Technavio's global neurodegenerative diseases therapeutics market is segmented as below:
By Indication
- Multiple sclerosis
- Alzheimers disease
- Parkinsons disease
- Huntingtons disease
- Others
By Drug Class
- Immunomodulators
- Interferons
- Decarboxylase inhibitors
- Dopamine agonists
- Others
By Route Of Administration
- Oral
- Injection
- Transdermal
By End-User
- Hospital pharmacy
- Retail pharmacy
- Online pharmacy
Geography
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Asia
- Rest of World (ROW)
- Rest of World (ROW)
This study identifies the growing aging population and neurological disease burden as one of the prime reasons driving the global neurodegenerative diseases therapeutics market growth during the next few years. Also, accelerated approvals for advanced neurotherapies and evolution of early detection and biomarker technologies will lead to sizable demand in the market.
The report on the global neurodegenerative diseases therapeutics market covers the following areas:
- Global neurodegenerative diseases therapeutics market sizing
- Global neurodegenerative diseases therapeutics market forecast
- Global neurodegenerative diseases therapeutics market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global neurodegenerative diseases therapeutics market vendors that include AbbVie Inc., Acadia Pharmaceuticals Inc., Amneal Pharmaceuticals Inc., Bayer AG, Biogen Inc., Bristol Myers Squibb Co., Dr. Reddys Laboratories Ltd., Eisai Co. Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, H. Lundbeck AS, Johnson and Johnson, Merck KGaA, Mitsubishi Tanabe Pharma Corp., Novartis AG, Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries, Supernus Pharmaceuticals Inc.. Also, the global neurodegenerative diseases therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Indication
- Executive Summary - Chart on Market Segmentation by Drug Class
- Executive Summary - Chart on Market Segmentation by Route of Administration
- Executive Summary - Chart on Market Segmentation by End-user
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- 2.3 Factors of disruption
- 2.4 Impact of drivers and challenges
3 Market Landscape
- 3.1 Market ecosystem
- 3.2 Market characteristics
- 3.3 Value chain analysis
4 Market Sizing
- 4.1 Market definition
- 4.2 Market segment analysis
- Market segments
- 4.3 Market size 2025
- 4.4 Market outlook: Forecast for 2025-2030
5 Historic Market Size
- 5.1 Global Neurodegenerative Diseases Therapeutics Market 2020 - 2024
- Historic Market Size - Data Table on Global Neurodegenerative Diseases Therapeutics Market 2020 - 2024 ($ million)
- 5.2 Indication segment analysis 2020 - 2024
- Historic Market Size - Indication Segment 2020 - 2024 ($ million)
- 5.3 Drug Class segment analysis 2020 - 2024
- Historic Market Size - Drug Class Segment 2020 - 2024 ($ million)
- 5.4 Route of Administration segment analysis 2020 - 2024
- Historic Market Size - Route of Administration Segment 2020 - 2024 ($ million)
- 5.5 End-user segment analysis 2020 - 2024
- Historic Market Size - End-user Segment 2020 - 2024 ($ million)
- 5.6 Geography segment analysis 2020 - 2024
- Historic Market Size - Geography Segment 2020 - 2024 ($ million)
- 5.7 Country segment analysis 2020 - 2024
- Historic Market Size - Country Segment 2020 - 2024 ($ million)
6 Qualitative Analysis
- 6.1 Impact of AI on Global Neurodegenerative Diseases Therapeutics Market
- 6.2 Impact of geopolitical conflicts on Global Neurodegenerative Diseases Therapeutics Market
7 Five Forces Analysis
- 7.1 Five forces summary
- Five forces analysis - Comparison between 2025 and 2030
- 7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2025 and 2030
- 7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2025 and 2030
- 7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2025 and 2030
- 7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2025 and 2030
- 7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2025 and 2030
- 7.7 Market condition
8 Market Segmentation by Indication
- 8.1 Market segments
- 8.2 Comparison by Indication
- 8.3 Multiple sclerosis - Market size and forecast 2025-2030
- 8.4 Alzheimers disease - Market size and forecast 2025-2030
- 8.5 Parkinsons disease - Market size and forecast 2025-2030
- 8.6 Huntingtons disease - Market size and forecast 2025-2030
- 8.7 Others - Market size and forecast 2025-2030
- 8.8 Market opportunity by Indication
- Market opportunity by Indication ($ million)
9 Market Segmentation by Drug Class
- 9.1 Market segments
- 9.2 Comparison by Drug Class
- 9.3 Immunomodulators - Market size and forecast 2025-2030
- 9.4 Interferons - Market size and forecast 2025-2030
- 9.5 Decarboxylase inhibitors - Market size and forecast 2025-2030
- 9.6 Dopamine agonists - Market size and forecast 2025-2030
- 9.7 Others - Market size and forecast 2025-2030
- 9.8 Market opportunity by Drug Class
- Market opportunity by Drug Class ($ million)
10 Market Segmentation by Route of Administration
- 10.1 Market segments
- 10.2 Comparison by Route of Administration
- 10.3 Oral - Market size and forecast 2025-2030
- 10.4 Injection - Market size and forecast 2025-2030
- 10.5 Transdermal - Market size and forecast 2025-2030
- 10.6 Market opportunity by Route of Administration
- Market opportunity by Route of Administration ($ million)
11 Market Segmentation by End-user
- 11.1 Market segments
- 11.2 Comparison by End-user
- 11.3 Hospital pharmacy - Market size and forecast 2025-2030
- 11.4 Retail pharmacy - Market size and forecast 2025-2030
- 11.5 Online pharmacy - Market size and forecast 2025-2030
- 11.6 Market opportunity by End-user
- Market opportunity by End-user ($ million)
12 Customer Landscape
- 12.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
13 Geographic Landscape
- 13.1 Geographic segmentation
- 13.2 Geographic comparison
- 13.3 North America - Market size and forecast 2025-2030
- 13.3.1 US - Market size and forecast 2025-2030
- 13.3.2 Canada - Market size and forecast 2025-2030
- 13.3.3 Mexico - Market size and forecast 2025-2030
- 13.4 Europe - Market size and forecast 2025-2030
- 13.4.1 Germany - Market size and forecast 2025-2030
- 13.4.2 UK - Market size and forecast 2025-2030
- 13.4.3 France - Market size and forecast 2025-2030
- 13.4.4 Italy - Market size and forecast 2025-2030
- 13.4.5 Spain - Market size and forecast 2025-2030
- 13.4.6 The Netherlands - Market size and forecast 2025-2030
- 13.5 Asia - Market size and forecast 2025-2030
- 13.5.1 China - Market size and forecast 2025-2030
- 13.5.2 Japan - Market size and forecast 2025-2030
- 13.5.3 India - Market size and forecast 2025-2030
- 13.5.4 South Korea - Market size and forecast 2025-2030
- 13.5.5 Singapore - Market size and forecast 2025-2030
- 13.5.6 Thailand - Market size and forecast 2025-2030
- 13.6 Rest of World (ROW) - Market size and forecast 2025-2030
- 13.6.1 Brazil - Market size and forecast 2025-2030
- 13.6.2 Saudi Arabia - Market size and forecast 2025-2030
- 13.6.3 South Africa - Market size and forecast 2025-2030
- 13.6.4 UAE - Market size and forecast 2025-2030
- 13.6.5 Argentina - Market size and forecast 2025-2030
- 13.6.6 Turkey - Market size and forecast 2025-2030
- 13.6.7 Egypt - Market size and forecast 2025-2030
- 13.6.8 Chile - Market size and forecast 2025-2030
- 13.7 Market opportunity by geography
- Market opportunity by geography ($ million)
- Data Tables on Market opportunity by geography ($ million)
14 Drivers, Challenges, and Opportunity
- 14.1 Market drivers
- Rapidly aging global demographic and rising disease prevalence
- Breakthroughs in biomarker discovery and early diagnostic technologies
- Increased funding and favorable regulatory pathways
- 14.2 Market challenges
- High attrition rates in clinical trial execution
- Prohibitive research expenditures and fragmented insurance coverage
- Strict regulatory compliance protocols and evolving safety thresholds
- 14.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2025 and 2030
- 14.4 Market opportunities
- Growing aging population and neurological disease burden
- Accelerated approvals for advanced neurotherapies
- Evolution of early detection and biomarker technologies
15 Competitive Landscape
- 15.1 Overview
- 15.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 15.3 Landscape disruption
- Overview on factors of disruption
- 15.4 Industry risks
- Impact of key risks on business
16 Competitive Analysis
- 16.1 Companies profiled
- Companies covered
- 16.2 Company ranking index
- Company ranking index
- 16.3 Market positioning of companies
- Matrix on companies position and classification
- 16.4 AbbVie Inc.
- AbbVie Inc. - Overview
- AbbVie Inc. - Business segments
- AbbVie Inc. - Key news
- AbbVie Inc. - Key offerings
- AbbVie Inc. - Segment focus
- SWOT
- 16.5 Acadia Pharmaceuticals Inc.
- Acadia Pharmaceuticals Inc. - Overview
- Acadia Pharmaceuticals Inc. - Product / Service
- Acadia Pharmaceuticals Inc. - Key offerings
- SWOT
- 16.6 Amneal Pharmaceuticals Inc.
- Amneal Pharmaceuticals Inc. - Overview
- Amneal Pharmaceuticals Inc. - Business segments
- Amneal Pharmaceuticals Inc. - Key offerings
- Amneal Pharmaceuticals Inc. - Segment focus
- SWOT
- 16.7 Bayer AG
- Bayer AG - Overview
- Bayer AG - Business segments
- Bayer AG - Key offerings
- Bayer AG - Segment focus
- SWOT
- 16.8 Biogen Inc.
- Biogen Inc. - Overview
- Biogen Inc. - Product / Service
- Biogen Inc. - Key offerings
- SWOT
- 16.9 Bristol Myers Squibb Co.
- Bristol Myers Squibb Co. - Overview
- Bristol Myers Squibb Co. - Product / Service
- Bristol Myers Squibb Co. - Key news
- Bristol Myers Squibb Co. - Key offerings
- SWOT
- 16.10 Dr. Reddys Laboratories Ltd.
- Dr. Reddys Laboratories Ltd. - Overview
- Dr. Reddys Laboratories Ltd. - Business segments
- Dr. Reddys Laboratories Ltd. - Key news
- Dr. Reddys Laboratories Ltd. - Key offerings
- Dr. Reddys Laboratories Ltd. - Segment focus
- SWOT
- 16.11 Eisai Co. Ltd.
- Eisai Co. Ltd. - Overview
- Eisai Co. Ltd. - Business segments
- Eisai Co. Ltd. - Key offerings
- Eisai Co. Ltd. - Segment focus
- SWOT
- 16.12 Eli Lilly and Co.
- Eli Lilly and Co. - Overview
- Eli Lilly and Co. - Product / Service
- Eli Lilly and Co. - Key offerings
- SWOT
- 16.13 F. Hoffmann La Roche Ltd.
- F. Hoffmann La Roche Ltd. - Overview
- F. Hoffmann La Roche Ltd. - Business segments
- F. Hoffmann La Roche Ltd. - Key news
- F. Hoffmann La Roche Ltd. - Key offerings
- F. Hoffmann La Roche Ltd. - Segment focus
- SWOT
- 16.14 GlaxoSmithKline Plc
- GlaxoSmithKline Plc - Overview
- GlaxoSmithKline Plc - Business segments
- GlaxoSmithKline Plc - Key news
- GlaxoSmithKline Plc - Key offerings
- GlaxoSmithKline Plc - Segment focus
- SWOT
- 16.15 Johnson and Johnson
- Johnson and Johnson - Overview
- Johnson and Johnson - Business segments
- Johnson and Johnson - Key news
- Johnson and Johnson - Key offerings
- Johnson and Johnson - Segment focus
- SWOT
- 16.16 Merck KGaA
- Merck KGaA - Overview
- Merck KGaA - Business segments
- Merck KGaA - Key news
- Merck KGaA - Key offerings
- Merck KGaA - Segment focus
- SWOT
- 16.17 Novartis AG
- Novartis AG - Overview
- Novartis AG - Business segments
- Novartis AG - Key news
- Novartis AG - Key offerings
- Novartis AG - Segment focus
- SWOT
- 16.18 Pfizer Inc.
- Pfizer Inc. - Overview
- Pfizer Inc. - Business segments
- Pfizer Inc. - Key news
- Pfizer Inc. - Key offerings
- Pfizer Inc. - Segment focus
- SWOT
17 Appendix
- 17.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
- 17.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 17.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 17.4 Research methodology
- Research methodology
- 17.5 Data procurement
- Information sources
- 17.6 Data validation
- Data validation
- 17.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 17.8 Data synthesis
- Data synthesis
- 17.9 360 degree market analysis
- 360 degree market analysis
- 17.10 List of abbreviations
- List of abbreviations
